Navigation Links
ImQuest Pharmaceuticals Receives FDA Approval to Initiate Clinical Trials of a Vaginal Gel for the Prevention of HIV Transmission to Women
Date:7/16/2014

FREDERICK, Md., July 16, 2014 /PRNewswire/ -- ImQuest Pharmaceuticals was recently notified by the US Food and Drug Administration of the approval of its Investigational New Drug (IND) application to study the safety in Phase 1 clinical trials of its vaginal gel containing the nonnucleoside reverse transcriptase HIV Inhibitor IQP-0528. Preclinical studies have shown that IQP-0528 is highly effective against virus strains found throughout the world, prevents HIV transmission in cultured cells, causes sterilization of cultures infected with HIV, and acts in concert with other approved HIV drugs to inhibit the virus. The IQP-0528 vaginal gel is being developed with the goal of preventing the sexual transmission of HIV to women throughout the world.

ImQuest plans to evaluate the safety of the IQP-0528 vaginal gel in a Phase I clinical trial at medical centers in the United States and expects to begin recruiting women for the trial by the end of the year. This marks the company's first product to receive FDA approval for clinical trials.

"The approval of our IND by the FDA is a major and highly significant milestone for ImQuest's Women's Health and Prevention programs focused on the protection of susceptible women from infection," said Dr. Robert Buckheit, Jr., President and Chief Scientific Officer of ImQuest. "In light of the unique properties of IQP-0528 we anticipate that the IQP-0528-containing gel will be a highly successful prevention agent and will be a first step towards our development of subsequent prevention and women's health products."

ImQuest Pharmaceuticals developed the HIV inhibitor in partnership with Samjin Pharmaceutical Co. Ltd of Seoul Korea. Preclinical testing was conducted by ImQuest BioSciences of Frederick, Maryland using the company's newly launched ImQuestSUCCESS™ platform, which enables the rapid identification of drug candidates with a high probability of clinical success early in the discovery and development process. Development of ImQuest's prevention products has been supported in part by the National Institutes of Health and the International Partnership for Microbicides, which is funded by The Bill and Melinda Gates Foundation and The United States Agency for International Development (USAID).

The company plans to submit a second IND to the FDA for approval to test IQP-0528 in a DuoGel™ formulation for protection of both vaginal and rectal virus transmission to men and women early next year – a product which will represent a major advancement for microbicide products in the pharmaceutical industry.

About ImQuest Pharmaceuticals
ImQuest Pharmaceuticals is a leading drug discovery and development company with a highly focused strategy of developing a proprietary portfolio of novel agents for the prevention of infectious disease as well as products for Women's Health. The pipeline includes vaginal gels, dual vaginal/rectal DuoGels™, films and intravaginal rings as prevention products and has significant efforts directed at the use of transdermal delivery of pharmaceutical products. The company has an exclusive development relationship with Samjin Pharmaceuticals with a right of first refusal to their products for the prevention and treatment of infectious disease. ImQuest Pharmaceuticals plans to strategically develop their topical microbicides product pipeline to provide prevention products to both men and women to inhibit the transmission of HIV and other sexually transmitted infectious (STI) organisms. ImQuest Pharmaceuticals' business model is to commercialize exciting new drugs with unique mechanisms of action both independently as well as in partnership with other pharmaceutical companies.  For more information, visit www.imquestls.com.

About ImQuest BioSciences
ImQuest BioSciences is a preclinical contract research and development company that evaluates the potential of new and novel pharmaceutical products. ImQuest provides expert laboratory research services to define the efficacy and toxicity of pharmaceutical products and specialize in the development of drugs, vaccines and biologic products for the treatment and prevention of infectious disease, cancer and inflammatory disease. ImQuest is committed to earning our client's trust and building long term relationships through collaboration, unwavering commitment to quality science and consistent and effective communication. ImQuest has recently released the ImQuestSUCCESS™ platform which will significantly expedite the development of pharmaceutical products with enhanced probability for successful clinical development. ImQuest understands that each product and each client is unique and strives to provide effective solutions. For more information, visit www.imquestbio.com.

Media Contact
Faye Coggins
301-696-0274

Logo - http://photos.prnewswire.com/prnh/20140715/127390


'/>"/>
SOURCE ImQuest BioSciences
Copyright©2014 PR Newswire.
All rights reserved

Related biology technology :

1. Cloud Pharmaceuticals Granted 1M Hours of Supercomputer Time to Target Orphan Diseases Including Malaria
2. Sunovion Pharmaceuticals Canada Inc. Announces Health Canada Approval of APTIOM(TM) (eslicarbazepine acetate) as a Once-Daily Adjunctive Treatment for Partial-Onset Seizures in Patients with Epilepsy
3. RXi Pharmaceuticals Receives US Notice of Allowance for a Key Patent Relating to its Self-Delivering Technology with sd-rxRNAs targeting CTGF, including RXI-109, for the Treatment of Fibrotic Disorders
4. Collaborations, FDA Approvals, Appointments, Patents, and Stock Movements - Research Report on Aetna, United Therapeutics, Perrigo, Arena Pharmaceuticals, and Keryx Biopharmaceuticals
5. Shimadzu’s New Aggregates Sizer Aggregation Analysis System for Biopharmaceuticals Enables Real-time Quantitative Analysis
6. Savient Receives Approval From Bankruptcy Court To Sell Substantially All Assets To Crealta Pharmaceuticals
7. Biotech Briefing: Advancing Biotechs Forging Ahead With Breaking News Developments: Alliqua, OncoMed Pharmaceuticals, EnteroMedics, Unilife, Amarin
8. Vanda Pharmaceuticals to Present at the 25th Annual Piper Jaffray Healthcare Conference
9. Actinium Pharmaceuticals Announces 2013 Annual Shareholder Meeting
10. Avanir Pharmaceuticals to Participate in Two Conferences in December
11. Jazz Pharmaceuticals Announces Participation at the Piper Jaffray Healthcare Conference on December 3
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/10/2017)... , ... October 10, 2017 ... ... cancer-focused pharmaceutical company advancing targeted antibody-drug conjugate (ADC) therapeutics, today confirmed licensing ... HPLN (Hybrid Polymerized Liposomal Nanoparticle), a technology developed in collaboration with Children’s ...
(Date:10/10/2017)... Parks Associates announced today that Tom Kerber , Director ... , October 11 in Scottsdale, Arizona . Kerber will ... safety and security products impact the competitive landscape. ... Parks Associates: Smart Home Devices: Main Purchase Driver ... "The residential security market has experienced continued growth, and the introduction of ...
(Date:10/10/2017)... ... October 10, 2017 , ... The Pittcon Program Committee ... honoring scientists who have made outstanding contributions to analytical chemistry and applied ... the world’s leading conference and exposition for laboratory science, which will be held ...
(Date:10/9/2017)... ... October 09, 2017 , ... At its national board meeting ... a professor in Harvard University’s Departments of Physics and Astronomy, has been selected for ... of the winning team for the 2015 Breakthrough Prize in Fundamental physics for the ...
Breaking Biology Technology:
(Date:5/23/2017)... GENOA, Italy , May 23, 2017  Hunova, the first robotic ... and trunk, has been officially launched in Genoa, Italy ... Europe and the USA . The ... launched on the market by the IIT spin-off Movendo Technology thanks to ... view the Multimedia News Release, please click: ...
(Date:4/19/2017)... York , April 19, 2017 ... as its vendor landscape is marked by the presence ... market is however held by five major players - ... Together these companies accounted for nearly 61% of the ... the leading companies in the global military biometrics market ...
(Date:4/11/2017)... , April 11, 2017 Crossmatch®, a ... authentication solutions, today announced that it has been ... Research Projects Activity (IARPA) to develop next-generation Presentation ... "Innovation has been a driving force ... program will allow us to innovate and develop ...
Breaking Biology News(10 mins):